JP6359175B2 - PARP阻害剤としての4H‐ピラゾロ[1,5‐α]ベンゾイミダゾール化合物のアナログ - Google Patents

PARP阻害剤としての4H‐ピラゾロ[1,5‐α]ベンゾイミダゾール化合物のアナログ Download PDF

Info

Publication number
JP6359175B2
JP6359175B2 JP2017504223A JP2017504223A JP6359175B2 JP 6359175 B2 JP6359175 B2 JP 6359175B2 JP 2017504223 A JP2017504223 A JP 2017504223A JP 2017504223 A JP2017504223 A JP 2017504223A JP 6359175 B2 JP6359175 B2 JP 6359175B2
Authority
JP
Japan
Prior art keywords
group
fluoro
imidazo
benzo
formamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017504223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017510653A (ja
Inventor
シュエハイ ワン
シュエハイ ワン
ジャオジョン ディン
ジャオジョン ディン
ヨン シュ
ヨン シュ
シュホエイ チェン
シュホエイ チェン
リエ リー
リエ リー
ガン リー
ガン リー
ロンホワ トゥ
ロンホワ トゥ
ツァイリン ワン
ツァイリン ワン
ヤン ユエ
ヤン ユエ
ジーボ ジャン
ジーボ ジャン
ハイリエン チェン
ハイリエン チェン
ウェンジエ スン
ウェンジエ スン
ルー ホワン
ルー ホワン
Original Assignee
フーベイ バイオ−ファーマシューティカル インダストリアル テクノロジカル インスティテュート インコーポレイテッド
フーベイ バイオ−ファーマシューティカル インダストリアル テクノロジカル インスティテュート インコーポレイテッド
ヒューマンウェル ヘルスケア (グループ) カンパニー リミテッド
ヒューマンウェル ヘルスケア (グループ) カンパニー リミテッド
メッドシャイン ディスカバリー インコーポレイテッド
メッドシャイン ディスカバリー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201410144173.0A external-priority patent/CN104974161B/zh
Application filed by フーベイ バイオ−ファーマシューティカル インダストリアル テクノロジカル インスティテュート インコーポレイテッド, フーベイ バイオ−ファーマシューティカル インダストリアル テクノロジカル インスティテュート インコーポレイテッド, ヒューマンウェル ヘルスケア (グループ) カンパニー リミテッド, ヒューマンウェル ヘルスケア (グループ) カンパニー リミテッド, メッドシャイン ディスカバリー インコーポレイテッド, メッドシャイン ディスカバリー インコーポレイテッド filed Critical フーベイ バイオ−ファーマシューティカル インダストリアル テクノロジカル インスティテュート インコーポレイテッド
Publication of JP2017510653A publication Critical patent/JP2017510653A/ja
Application granted granted Critical
Publication of JP6359175B2 publication Critical patent/JP6359175B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2017504223A 2014-04-10 2015-03-30 PARP阻害剤としての4H‐ピラゾロ[1,5‐α]ベンゾイミダゾール化合物のアナログ Active JP6359175B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410144173.0A CN104974161B (zh) 2014-04-10 2014-04-10 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物
CN201410144173.0 2014-04-10
CN201510113090 2015-03-13
CN201510113090.X 2015-03-13
PCT/CN2015/075363 WO2015154630A1 (zh) 2014-04-10 2015-03-30 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物

Publications (2)

Publication Number Publication Date
JP2017510653A JP2017510653A (ja) 2017-04-13
JP6359175B2 true JP6359175B2 (ja) 2018-07-18

Family

ID=54287319

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017504223A Active JP6359175B2 (ja) 2014-04-10 2015-03-30 PARP阻害剤としての4H‐ピラゾロ[1,5‐α]ベンゾイミダゾール化合物のアナログ

Country Status (22)

Country Link
US (1) US9856262B2 (ru)
EP (1) EP3130592B1 (ru)
JP (1) JP6359175B2 (ru)
KR (1) KR101921486B1 (ru)
CN (1) CN106459057B (ru)
AU (1) AU2015245786B2 (ru)
BR (1) BR112016023397B1 (ru)
CA (1) CA2944801C (ru)
DK (1) DK3130592T3 (ru)
ES (1) ES2754590T3 (ru)
HU (1) HUE047410T2 (ru)
IL (1) IL248258B (ru)
MX (1) MX368496B (ru)
NZ (1) NZ725165A (ru)
PL (1) PL3130592T3 (ru)
PT (1) PT3130592T (ru)
RU (1) RU2672722C2 (ru)
SA (1) SA516380051B1 (ru)
SG (1) SG11201608438YA (ru)
TW (1) TWI671301B (ru)
WO (1) WO2015154630A1 (ru)
ZA (1) ZA201607736B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104974161B (zh) * 2014-04-10 2019-11-01 湖北生物医药产业技术研究院有限公司 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物
CN108137598B (zh) * 2015-09-30 2021-02-12 湖北生物医药产业技术研究院有限公司 4H-吡唑并[1,5-α]苯并咪唑类化合物的盐型、晶型及其制备方法和中间体
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
MX2019012803A (es) 2017-04-27 2020-01-23 Bayer Animal Health Gmbh Nuevos derivados de pirazol biciclicos.
CN115028641B (zh) * 2022-07-19 2024-05-28 湖南大学 一种钴催化合成5,8-双官能团取代咪唑并[1,2-a]吡嗪类化合物的方法
CN116969954B (zh) * 2023-09-21 2023-11-28 广东省农业科学院农业质量标准与监测技术研究所 一类含内酰胺的三环稠合杂环化合物及其应用
CN117534677B (zh) * 2024-01-09 2024-03-12 广东省农业科学院农业质量标准与监测技术研究所 一类含亚胺的三环稠合杂环化合物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916051A (en) * 1987-04-07 1990-04-10 Konica Corporation Silver halide color photographic light-sensitive material
JP4926720B2 (ja) * 2003-12-22 2012-05-09 スミスクライン ビーチャム (コーク) リミテッド Crf受容体アンタゴニストおよびそれらに関連する方法
WO2007076127A2 (en) 2005-12-22 2007-07-05 Biogen Idec Ma Inc Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
WO2007144669A1 (en) 2006-06-15 2007-12-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrazolo[1,5-a]quinazolin-5(4h)-ones as inhibitors of poly(adp-ribose)polymerase (parp)
CA2655561C (en) * 2006-06-20 2014-10-21 Abbott Laboratories Pyrazoloquinazolinones as parp inhibitors
GB0701273D0 (en) 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
ES2535511T3 (es) 2012-04-26 2015-05-12 Helmut Schickaneder Ésteres de bendamustina y compuestos relacionados, y uso médico de los mismos
US9174995B2 (en) * 2012-05-04 2015-11-03 Merck Patent Gmbh Pyrrolotriazinone derivatives
EP2666775A1 (en) * 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
WO2013182580A1 (en) 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
AU2013288265B2 (en) 2012-07-09 2017-04-06 Lupin Limited Tetrahydroquinazolinone derivatives as PARP inhibitors
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
RS59921B1 (sr) 2012-08-08 2020-03-31 Merck Patent Gmbh (aza-)izohinolinon derivati
CN104974161B (zh) 2014-04-10 2019-11-01 湖北生物医药产业技术研究院有限公司 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物

Also Published As

Publication number Publication date
EP3130592A4 (en) 2017-09-06
EP3130592A1 (en) 2017-02-15
BR112016023397B1 (pt) 2022-08-16
WO2015154630A1 (zh) 2015-10-15
RU2016144202A3 (ru) 2018-05-15
NZ725165A (en) 2018-04-27
MX2016013265A (es) 2017-05-03
KR101921486B1 (ko) 2018-11-26
RU2016144202A (ru) 2018-05-15
SA516380051B1 (ar) 2020-05-17
US9856262B2 (en) 2018-01-02
CN106459057A (zh) 2017-02-22
SG11201608438YA (en) 2016-11-29
AU2015245786B2 (en) 2018-03-15
HUE047410T2 (hu) 2020-04-28
TW201620913A (zh) 2016-06-16
KR20170005807A (ko) 2017-01-16
CA2944801C (en) 2019-02-12
US20170029430A1 (en) 2017-02-02
BR112016023397A2 (ru) 2017-08-15
MX368496B (es) 2019-10-04
EP3130592B1 (en) 2019-08-14
JP2017510653A (ja) 2017-04-13
PT3130592T (pt) 2019-11-21
PL3130592T3 (pl) 2020-05-18
RU2672722C2 (ru) 2018-11-19
AU2015245786A1 (en) 2016-11-03
TWI671301B (zh) 2019-09-11
DK3130592T3 (da) 2019-11-04
ES2754590T3 (es) 2020-04-20
IL248258B (en) 2018-11-29
CA2944801A1 (en) 2015-10-15
ZA201607736B (en) 2017-09-27
CN106459057B (zh) 2019-06-07

Similar Documents

Publication Publication Date Title
JP6359175B2 (ja) PARP阻害剤としての4H‐ピラゾロ[1,5‐α]ベンゾイミダゾール化合物のアナログ
JP6976953B2 (ja) Rock阻害剤としてのスピロヘプタンサリチルアミドおよび関連性化合物
EP3538525B1 (en) 3-substituted propionic acids as alpha v integrin inhibitors
JP5959541B2 (ja) Trk阻害剤としてのピラゾロ[1,5−a]ピリジン
JP6581111B2 (ja) Rhoキナーゼ阻害剤としてのイソキノリンスルホン誘導体
CN104974161B (zh) 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物
EP2721016B1 (en) Trpv4 antagonists
KR20190005838A (ko) 이중 lsd1/hdac 억제제로서 사이클로프로필-아마이드 화합물
CN116323580A (zh) 通过egfr抑制剂与e3连接酶配体的缀合降解(egfr)和使用方法
MX2013005603A (es) Derivados de pirrolopiridina sustituidos con ciclobutilo como inhibidores de janus cinasas (jak).
WO2020186220A1 (en) Compounds as inhibitors of macrophage migration inhibitory factor
TW202237597A (zh) 新型egfr降解劑
CN117042769A (zh) 作为布鲁顿酪氨酸激酶(btk)降解剂的取代的吡咯并嘧啶和吡唑并嘧啶
JP7340519B2 (ja) mTORC1/2二重阻害剤としてのピリドピリミジン系化合物
JP6977038B2 (ja) Gsk−3阻害剤
JP2019518052A (ja) Akt阻害剤としてのジヒドロピラゾロアゼピン系化合物
JP2024527623A (ja) 癌の治療のためのhpk1阻害剤としての置換ピラジン-2-カルボキサミド阻害剤
WO2024182447A1 (en) Compounds and methods for modulating ras-pi3k
WO2024220399A1 (en) Pyrazolotriazinecarbonitriles useful as kinase inhibitors
TW202330519A (zh) 作為tam抑制劑的吡唑并吡啶化合物
CN117659023A (zh) 吡啶乙酰胺类衍生物、包含其的药物组合物及其医药用途
TW202416963A (zh) Egfr抑制劑及其用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180316

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180529

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180619

R150 Certificate of patent or registration of utility model

Ref document number: 6359175

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250